Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879875 | 0.91 | SRD5A1 (0.42) | SRD5A1 | |
| SCHEMBL17993583 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP26A1GRM2CES2 | |
| SCHEMBL17993592 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP26A1GRM2CES2 | |
| SCHEMBL11379782 | 0.81 | HTR6 (0.39) | CYP26A1 | |
| SCHEMBL598931 | 0.80 | BRD4 (0.42) | HCRTR1HCRTR2CYP26A1BRD4 | |
| SCHEMBL598932 | 0.80 | BRD4 (0.42) | HCRTR1HCRTR2CYP26A1BRD4 | |
| SCHEMBL14900495 | 0.80 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP26A1GRM2MMP2 | |
| SCHEMBL598567 | 0.79 | HCRTR1 (0.54) | HCRTR1HCRTR2FAAHMGLLMMP2 | |
| SCHEMBL3395452 | 0.79 | CYP26A1 (0.42) | HCRTR1HCRTR2CYP26A1FAAHMMP2 | |
| SCHEMBL3395450 | 0.79 | CYP26A1 (0.42) | HCRTR1HCRTR2CYP26A1FAAHMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8716495-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | HCRTR1 2568/4885HCRTR2 2878/4885CYP26A1 76/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | HCRTR1 2568/4885HCRTR2 2878/4885CYP26A1 76/4885 |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | HCRTR1 2568/4885HCRTR2 2878/4885CYP26A1 76/4885 |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | HCRTR1 2568/4885HCRTR2 2878/4885CYP26A1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.